查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703259

下一代乳癌診斷和篩檢市場—全球產業規模、佔有率、趨勢、機會和預測，按技術、生物標記、癌症亞型、產品、最終用戶、地區和競爭細分，2020 年至 2030 年

Next-Generation Breast Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Biomarker, By Cancer Sub-Type, By Offering, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球下一代乳癌診斷和篩檢市場價值為 46.5 億美元，預計到 2030 年將達到 85.3 億美元，複合年成長率為 10.61%。下一代乳癌診斷和篩檢方法是指檢測和診斷乳癌的先進和創新方法。這些方法結合了尖端技術、分子見解和個人化方法，以提高乳癌檢測、診斷和風險評估的準確性和有效性。下一代方法可以根據特定的基因標記對乳癌進行分子亞型分析。這種亞型分析提供了對腫瘤行為的洞察，並有助於確定最合適的治療策略。常見的亞型包括荷爾蒙受體陽性、HER2陽性和三陰性乳癌。全球乳癌發生率的上升是一個重要促進因素。隨著乳癌發病率持續上升，對早期發現疾病的先進診斷和篩檢方法的需求也在增加。

市場概覽
預測期 2026-2030
2024年市場規模 46.5億美元
2030年市場規模 85.3億美元
2025-2030 年複合年成長率 10.61%
成長最快的領域 下一代定序（NGS）
最大的市場 北美洲

乳房影像、基因檢測和分子診斷技術的不斷進步提高了乳癌的準確性和早期檢測能力，推動了對這些技術的需求。個人化醫療的轉變導致對提供有關患者乳癌亞型和基因特徵的個人化資訊的診斷測試的需求增加。這些資訊可指導治療決策。乳癌宣傳活動和促進早期發現的措施鼓勵更多女性定期進行乳癌篩檢，促進了市場成長。

關鍵市場促進因素

技術進步

主要市場挑戰

道德和法律問題

主要市場趨勢

多組學資料整合

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球下一代乳癌診斷與篩檢市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依技術（即時 PCR、免疫組織化學 (IHC)、次世代定序 (NGS)、螢光原位雜合技術 (FISH)、其他）
    • 依生物標記（BRCA1/2、ER/PR 受體、HER-2、其他）
    • 依癌症亞型（管腔 A、管腔 B、三陰性/基底細胞樣、人類表皮生長因子受體 2 (HER-2) 富集型）
    • 透過提供（產品、服務）
    • 按最終使用者（醫院和診所、診斷中心和參考實驗室、學術和研究機構）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：亞太地區下一代乳癌診斷與篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第7章：歐洲下一代乳癌診斷與篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第8章：北美下一代乳癌診斷與篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第9章：南美洲下一代乳癌診斷與篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲下一代乳癌診斷和篩檢市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球下一代乳癌診斷與篩檢市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

  • Abbott Laboratories
  • Agendia Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • BGI Genomics Co., Ltd.
  • CENTOGENE NV
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Lucence Diagnostics Pte Ltd.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 16770

Global Next-Generation Breast Cancer Diagnostic and Screening Market was valued at USD 4.65 Billion in 2024 and is expected to reach USD 8.53 Billion in the forecast period with a CAGR of 10.61% through 2030. Next-generation breast cancer diagnostic and screening methods refer to advanced and innovative approaches to detecting and diagnosing breast cancer. These methods incorporate cutting-edge technologies, molecular insights, and personalized approaches to improve the accuracy and effectiveness of breast cancer detection, diagnosis, and risk assessment. Next-generation methods enable the molecular subtyping of breast cancer based on specific genetic markers. This subtyping provides insights into the tumor's behavior and helps determine the most appropriate treatment strategy. Common subtypes include hormone receptor-positive, HER2-positive, and triple-negative breast cancer. The increasing incidence of breast cancer worldwide has been a significant driver. As breast cancer rates continue to rise, the demand for advanced diagnostic and screening methods to detect the disease at an early stage has also increased.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.65 Billion
Market Size 2030USD 8.53 Billion
CAGR 2025-203010.61%
Fastest Growing SegmentNext-Generation Sequencing (NGS)
Largest MarketNorth America

Ongoing technological advancements in breast imaging, genetic testing, and molecular diagnostics have improved the accuracy and early detection of breast cancer, driving demand for these technologies. The shift toward personalized medicine has led to an increased demand for diagnostic tests that provide individualized information about a patient's breast cancer subtype and genetic profile. This information guides treatment decisions. Breast cancer awareness campaigns and initiatives promoting early detection have encouraged more women to undergo regular breast cancer screening, contributing to market growth.

Key Market Drivers

Advancements in Technology

Digital mammography has largely supplanted traditional film mammography, offering enhanced image quality, streamlined storage and retrieval, and the capability to manipulate images for improved visualization of breast tissue. As of June 2023, the U.S. Food and Drug Administration reported that 87% of mammography facilities in the United States have adopted 3D mammography systems, also known as breast tomosynthesis, which capture multiple X-ray images from different angles to create a three-dimensional representation of the breast. This technology has been shown to reduce false positives and improve cancer detection, particularly in women with dense breast tissue.

Breast Magnetic Resonance Imaging (MRI) utilizes powerful magnets and radio waves to generate detailed images of breast tissue, proving especially useful for assessing disease extent and detecting tumors in high-risk women. Advanced ultrasound technologies, including elastography and contrast-enhanced ultrasound, offer additional insights into breast lesions, aiding in distinguishing between benign and malignant tumors. Genetic testing has advanced with next-generation sequencing, allowing simultaneous analysis of multiple genes to comprehensively assess mutations associated with breast cancer.

Key Market Challenges

Ethical and Legal Issues

As next-generation diagnostic and screening methods generate large volumes of sensitive patient data, ensuring privacy and data security becomes paramount. Ethical concerns arise regarding the storage, sharing, and protection of patient genetic and medical information. Patients must provide informed consent before undergoing genetic testing or other screening procedures. Ensuring that patients fully understand the implications of the tests, including potential psychological and medical consequences, is an ethical imperative. Concerns about genetic discrimination in employment, insurance, and other areas may deter individuals from undergoing genetic testing. Legal protections against such discrimination are essential to address these concerns. Ethical and legal questions arise about who owns the genetic and medical data generated through screening. This includes issues related to data access, sharing, and commercialization. Next-generation screening technologies must adhere to regulatory standards to ensure safety, accuracy, and efficacy. Navigating the complex regulatory landscape can be a challenge for companies and healthcare providers. Ethical issues related to healthcare equity and access arise when next-generation screening technologies are not equally available to all populations. Disparities in access can lead to unequal health outcomes.

Key Market Trends

Integration of Multi-Omics Data

Multi-omics approaches enable healthcare providers to obtain a detailed profile of breast cancer at the molecular level. This includes information on genetic mutations, gene expression patterns, protein activity, metabolite levels, and epigenetic modifications. Integration of multi-omics data allows for precise molecular subtyping of breast cancer, which helps tailor treatment strategies based on the unique characteristics of each patient's tumor. This approach enhances the effectiveness of targeted therapies and minimizes unnecessary treatments. Multi-omics data analysis can identify biomarkers associated with early-stage breast cancer and risk prediction. This aids in early detection and risk assessment, enabling healthcare providers to intervene at an earlier, more treatable stage. Multi-omics analysis identifies specific molecular targets within breast cancer cells that can be exploited for treatment. This leads to the development of targeted therapies and more effective treatment options. Multi-omics data can be used to monitor a patient's response to treatment over time. Changes in gene expression, protein activity, or metabolite levels can indicate treatment efficacy or the need for therapeutic adjustments.

Key Market Players

  • Abbott Laboratories
  • Agendia Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Genomics Co., Ltd.
  • CENTOGENE N.V
  • Danaher Corporation
  • Exact Sciences Corporation
  • Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Lucence Diagnostics Pte Ltd.

Report Scope:

In this report, the Global Next-Generation Breast Cancer Diagnostic and Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next-Generation Breast Cancer Diagnostic and Screening Market, By Technology:

  • Real-Time PCR
  • Immunohistochemistry (IHC)
  • Next-Generation Sequencing (NGS)
  • Fluorescence In-Situ Hybridization (FISH)
  • Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Biomarker:

  • BRCA1/2
  • ER/PR Receptors
  • HER-2
  • Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Cancer Sub-Type:

  • Luminal A
  • Luminal B
  • Triple Negative/Basal Like
  • Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

Next-Generation Breast Cancer Diagnostic and Screening Market, By Offering:

  • Products
  • Services

Next-Generation Breast Cancer Diagnostic and Screening Market, By End User:

  • Hospitals and Clinics
  • Diagnostic Centers, and Reference Labs
  • Academic and Research Institutes

Next-Generation Breast Cancer Diagnostic and Screening Market, By region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation Breast Cancer Diagnostic and Screening Market.

Available Customizations:

Global Next-Generation Breast Cancer Diagnostic and Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others)
    • 5.2.2. By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others)
    • 5.2.3. By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched)
    • 5.2.4. By Offering (Products, Services)
    • 5.2.5. By End User (Hospitals and Clinics, Diagnostic Centers, and Reference Labs, Academic and Research Institutes)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Biomarker
    • 6.2.3. By Cancer Sub-Type
    • 6.2.4. By Offering
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Biomarker
        • 6.3.1.2.3. By Cancer Sub-Type
        • 6.3.1.2.4. By Offering
        • 6.3.1.2.5. By End User
    • 6.3.2. India Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Biomarker
        • 6.3.2.2.3. By Cancer Sub-Type
        • 6.3.2.2.4. By Offering
        • 6.3.2.2.5. By End User
    • 6.3.3. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Biomarker
        • 6.3.3.2.3. By Cancer Sub-Type
        • 6.3.3.2.4. By Offering
        • 6.3.3.2.5. By End User
    • 6.3.4. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Technology
        • 6.3.4.2.2. By Biomarker
        • 6.3.4.2.3. By Cancer Sub-Type
        • 6.3.4.2.4. By Offering
        • 6.3.4.2.5. By End User
    • 6.3.5. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Technology
        • 6.3.5.2.2. By Biomarker
        • 6.3.5.2.3. By Cancer Sub-Type
        • 6.3.5.2.4. By Offering
        • 6.3.5.2.5. By End User

7. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Biomarker
    • 7.2.3. By Cancer Sub-Type
    • 7.2.4. By Offering
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Biomarker
        • 7.3.1.2.3. By Cancer Sub-Type
        • 7.3.1.2.4. By Offering
        • 7.3.1.2.5. By End User
    • 7.3.2. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Biomarker
        • 7.3.2.2.3. By Cancer Sub-Type
        • 7.3.2.2.4. By Offering
        • 7.3.2.2.5. By End User
    • 7.3.3. Spain Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Biomarker
        • 7.3.3.2.3. By Cancer Sub-Type
        • 7.3.3.2.4. By Offering
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Biomarker
        • 7.3.4.2.3. By Cancer Sub-Type
        • 7.3.4.2.4. By Offering
        • 7.3.4.2.5. By End User
    • 7.3.5. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Biomarker
        • 7.3.5.2.3. By Cancer Sub-Type
        • 7.3.5.2.4. By Offering
        • 7.3.5.2.5. By End User

8. North America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Biomarker
    • 8.2.3. By Cancer Sub-Type
    • 8.2.4. By Offering
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Biomarker
        • 8.3.1.2.3. By Cancer Sub-Type
        • 8.3.1.2.4. By Offering
        • 8.3.1.2.5. By End User
    • 8.3.2. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Biomarker
        • 8.3.2.2.3. By Cancer Sub-Type
        • 8.3.2.2.4. By Offering
        • 8.3.2.2.5. By End User
    • 8.3.3. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Biomarker
        • 8.3.3.2.3. By Cancer Sub-Type
        • 8.3.3.2.4. By Offering
        • 8.3.3.2.5. By End User

9. South America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Biomarker
    • 9.2.3. By Cancer Sub-Type
    • 9.2.4. By Offering
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Biomarker
        • 9.3.1.2.3. By Cancer Sub-Type
        • 9.3.1.2.4. By Offering
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Biomarker
        • 9.3.2.2.3. By Cancer Sub-Type
        • 9.3.2.2.4. By Offering
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Biomarker
        • 9.3.3.2.3. By Cancer Sub-Type
        • 9.3.3.2.4. By Offering
        • 9.3.3.2.5. By End User

10. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Biomarker
    • 10.2.3. By Cancer Sub-Type
    • 10.2.4. By Offering
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Biomarker
        • 10.3.1.2.3. By Cancer Sub-Type
        • 10.3.1.2.4. By Offering
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Biomarker
        • 10.3.2.2.3. By Cancer Sub-Type
        • 10.3.2.2.4. By Offering
        • 10.3.2.2.5. By End User
    • 10.3.3. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Biomarker
        • 10.3.3.2.3. By Cancer Sub-Type
        • 10.3.3.2.4. By Offering
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Next-Generation Breast Cancer Diagnostic and Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Abbott Laboratories
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Agendia Inc.
  • 16.3. Agilent Technologies, Inc.
  • 16.4. Bio-Rad Laboratories, Inc.
  • 16.5. BGI Genomics Co., Ltd.
  • 16.6. CENTOGENE N.V.
  • 16.7. Danaher Corporation
  • 16.8. Exact Sciences Corporation
  • 16.9. F. Hoffmann-La Roche Ltd.
  • 16.10. Illumina, Inc.
  • 16.11. Thermo Fisher Scientific Inc.
  • 16.12. Lucence Diagnostics Pte Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer